Stock Update (NASDAQ:AMGN): FDA Accepts Amgen’s New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide

[PR Newswire] – THOUSAND OAKS, Calif., Nov. 6, 2015 /PRNewswire/ — Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen’s New Drug Application (NDA) for . . . → Read More: Stock Update (NASDAQ:AMGN): FDA Accepts Amgen’s New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide Similar Articles: Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen, Cytokinetics heart failure drug succeeds in mid-stage study Company Update (NASDAQ:AMGN): Europe gets Amgen cholesterol drug for 50-60 pct of U.S. price Stock Update: Amgen Inc (NASDAQ:AMGN) – FDA panel backs Amgen’s cholesterol drug for high-risk patients